Restenosis related to percutaneous coronary intervention has been solved?

References

• Silber S., Albertsson P., Aviles F. F., Camici P. G., Colombo A., Hamm C., et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26: 804
   PubMed Web of Science ®Google Scholar
• Lemos P. A., Serruys P. W., van Domburg R. T., Saia F., Arampatzis C. A., Hoye A., et al. Unrestricted utilization of sirolimus‐eluting stents compared with conventional bare stent implantation in the “real world”: the Rapamycin‐Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004; 109: 190–5
   PubMed Web of Science ®Google Scholar
• Greenberg D., Bakhai A., Cohen D. J. Can we afford to eliminate restenosis? Can we afford not to?. J Am Coll Cardiol 2004; 43: 513–8
   PubMed Web of Science ®Google Scholar
• Moses J. W., Leon M. B., Popma J. J., Fitzgerald P., Holmes D. R., O'Shaughnessy C., et al. Sirolimus‐eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315–23
   PubMed Web of Science ®Google Scholar
• Stone G. W., Ellis S. G., Cox D. A., Hermiller J., O'Shaughnessy C., Mann J. T., et al. A polymer‐based, paclitaxel‐eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221–31
   PubMed Web of Science ®Google Scholar
• Cutlip D. E., Chauhan M. S., Baim D. S., Ho K. K. L., Popma J. J., Carrozza J. P., et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol 2002; 40: 2082–9
   PubMed Web of Science ®Google Scholar
• Sindermann J. R., Verin V., Hopewell J. W., Rodemann H. P., Hendry J. H. Biological aspects of radiation and drug‐eluting stents for the prevention of restenosis. Cardiovasc Res 2004; 63: 22–30
   PubMed Web of Science ®Google Scholar
• Donners M. M., Daemen M. J., Cleutjens K. B., Heeneman S. Inflammation and restenosis: implications for therapy. Ann Med 2003; 35: 523–31
   PubMed Web of Science ®Google Scholar
• Schwartz R. S. Pathophysiology of restenosis: interaction of thrombosis, hyperplasia, and/or remodeling. Am J Cardiol 1998; 81: 14E–17E
   Google Scholar
• Costa M. A., Simon D. I. Molecular basis of restenosis and drug‐eluting stents. Circulation 2005; 111: 2257
   PubMed Web of Science ®Google Scholar
• Farb A., Sangiorgi G., Carter A. J., Walley V. M., Edwards W. D., Schwartz R. S., et al. Pathology of acute and chronic coronary stenting in humans. Circulation 1999; 99: 44–52
   PubMed Web of Science ®Google Scholar
• Welt F. G. P., Rogers C. Inflammation and Restenosis in the Stent Era. Arterioscler Thromb Vasc Biol 2002; 22: 1769–76
   PubMed Web of Science ®Google Scholar
• Sartore S., Chiavegato A., Faggin E., Franch R., Puato M., Ausoni S., et al. Contribution of Adventitial Fibroblasts to Neointima Formation and Vascular Remodeling: From Innocent Bystander to Active Participant. Circ Res 2001; 89: 1111–21
   PubMed Web of Science ®Google Scholar
• Libby P., Schwartz D., Brogi E., Tanaka H., Clinton S. K. A cascade model for restenosis. A special case of atherosclerosis progression. Circulation 1992; 86: III47–III52
   PubMedGoogle Scholar
• Clowes A. W., Reidy M. A., Clowes M. M. Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab Invest 1983; 49: 327–33
   PubMed Web of Science ®Google Scholar
• Grewe P. H., Deneke T., Machraoui A., Barmeyer J., Muller K. M. Acute and chronic tissue response to coronary stent implantation: pathologic findings in human specimen. J Am Coll Cardiol 2000; 35: 157–63
   PubMed Web of Science ®Google Scholar
• Losordo D. W., Isner J. M., Diaz‐Sandoval L. J. Endothelial Recovery: The Next Target in Restenosis Prevention. Circulation 2003; 107: 2635–7
   Google Scholar
• Cutlip D. E., Chhabra A. G., Baim D. S., Chauhan M. S., Marulkar S., Massaro J., et al. Beyond restenosis. Five‐year clinical outcomes from second‐generation coronary stent trials. Circulation 2004; 110: 1226
   PubMed Web of Science ®Google Scholar
• Karha J., Bhatt D. L. Percutaneous coronary intervention in diabetics. Rev Endocr Metab Disord 2004; 5: 277–85
   Google Scholar
• Hermiller J. B., Raizner A., Cannon L., Gurbel P. A., Kutcher M. A., Wong S. C., et al. Outcomes with the polymer‐based paclitaxel‐eluting TAXUS stent in patients with diabetes mellitus. The TAXUS‐IV trial. J Am Coll Cardiol 2005; 45: 1172
   PubMed Web of Science ®Google Scholar
• Kastrati A., Schulen H., Schomig A. Stenting for small coronary vessels: a contestable winner (Editorial Comment). J Am Col Cardiol 2001; 38: 1604–7
   PubMed Web of Science ®Google Scholar
• Mauri L., O'Malley A. J., Cutlip D. E., Ho K. K., Popma J. J., Chauhan M. S., et al. Effects of Stent Length and Lesion Length on Coronary Restenosis. Am J Cardiol 2004; 93: 1340
   PubMed Web of Science ®Google Scholar
• Gomma A. H., Hirschfield G. M., Gallimore J. R., Jr., Lowe G. D., Pepys M. B., Fox K. M. Preprocedural inflammatory markers do not predict restenosis after successful coronary stenting. Am Heart J 2004; 147: 1071–7
   PubMed Web of Science ®Google Scholar
• Rittersma S. Z., de Winter R. J., Koch K. T., Schotborgh C. E., Bax M., Heyde G. S., et al. Preprocedural C‐reactive protein is not associated with angiographic restenosis or target lesion revascularization after coronary artery stent placement. Clin Chem 2004; 50: 1589–96
   Google Scholar
• Karaca I., Aydin K., Yavuzkir M., Ilkay E., Akbulut M., Isik A., et al. Predictive value of C‐reactive protein in patients with unstable angina pectoris undergoing coronary artery stent implantation. J Int Med Res 2005; 33: 389–96
   Google Scholar
• Dibra A., Mehilli J., Braun S., Hadamitzky M., Baum H., Dirschinger J., et al. Inflammatory response after intervention assessed by serial C‐reactive protein measurements correlates with restenosis in patients treated with coronary stenting. Am Heart J 2005; 150: 344–50
   Google Scholar
• Lange H., Suryapranata H., De Luca G., Borner C., Dille J., Kallmayer K., et al. Folate therapy and in‐stent restenosis after coronary stenting. N Engl J Med 2004; 350: 2673–81
   PubMed Web of Science ®Google Scholar
• Mody V. H., Durairaj A., Mehra A. O. Pharmacological approaches to prevent restenosis. Restenosis: A Guide to Therapy., D. P Faxon, editor. Martin Durnitz, LondonUK 2001; p. 97–112, In
   Google Scholar
• Kuchulakanti P., Waksman R. Therapeutic potential of oral antiproliferative agents in the prevention of coronary restenosis. Drugs 2004; 64: 2379–88
   Google Scholar
• Ward M. R., Agrotis A., Kanellakis P., Hall J., Jennings G., Bobik A. Tranilast Prevents Activation of Transforming Growth Factor‐{beta} System, Leukocyte Accumulation, and Neointimal Growth in Porcine Coronary Arteries After Stenting. Arterioscler Thromb Vasc Biol 2002; 22: 940–8
   PubMed Web of Science ®Google Scholar
• Holmes D. R., Jr., Savage M., Lablanche J. M., Grip L., Serruys P. W., Fitzgerald P., et al. Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) Trial. Circulation 2002; 106: 1243–50
   PubMed Web of Science ®Google Scholar
• Douglas J. S., Holmes D. R., Kereiakis D. J., Grines C. L., Block E., Ghazzal Z. M., et al. Coronary stent restenosis in patients treated with cilostazol (CREST). Circulation 2005; 112: 2826–32
   PubMed Web of Science ®Google Scholar
• Law R. E., Meehan W. P., Xi X. P., Graf K., Wuthrich D. A., Coats W., et al. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 1996; 98: 1897–905
   PubMed Web of Science ®Google Scholar
• Bruemmer D., Law R. E. Thiazolidinedione regulation of smooth muscle cell proliferation. Am J Med 2003; 115((Suppl 8A))87S–92S
   Google Scholar
• Takagi T., Yamamuro A., Tamita K., Yamabe K., Katayama M., Morioka S., et al. Impact of troglitazone on coronary stent implantation using small stents in patients with type 2 diabetes mellitus. Am J Cardiol 2002; 89: 318–22
   PubMed Web of Science ®Google Scholar
• Tardif J. C., Gregoire J., Schwartz L., Title L., Laramee L., Reeves F., et al. Effects of AGI‐1067 and probucol after percutaneous coronary interventions. Circulation 2003; 107: 552–8
   PubMed Web of Science ®Google Scholar
• Waksman R., Ajani A. E., Pichard A. D., Torguson R., Pinnow E., Canos D., et al. Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the Oral Rapamune to Inhibit Restenosis (ORBIT) study. J Am Coll Cardiol 2004; 44: 1386–92
   PubMed Web of Science ®Google Scholar
• Hausleiter J., Kastrati A., Mehilli J., Vogeser M., Zohlnhofer D., Schuhlen H., et al. OSIRIS Investigators. Randomized, double‐blind, placebo‐controlled trial of oral sirolimus for restenosis prevention in patients with in‐stent restenosis: the Oral Sirolimus to Inhibit Recurrent In‐stent Stenosis (OSIRIS) trial. Circulation 2004; 110: 790–5
   PubMed Web of Science ®Google Scholar
• Fischman D. L., Leon M. B., Baim D. S., Schatz R. A., Savage M. P., Penn I., et al. A randomized comparison of coronary‐stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994; 331: 496–501
   PubMed Web of Science ®Google Scholar
• Serruys P. W., de Jaegere P., Kiemeneij F., Macaya C., Rutsch W., Heyndrickx G., et al. A comparison of balloon‐expandable‐stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994; 331: 489–95
   PubMed Web of Science ®Google Scholar
• Serruys P. W., van Hout B., Bonnier H., Legrand V., Garcia E., Macaya C., et al. Randomised comparison of implantation of heparin‐coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet 1998; 352: 673–81
   PubMed Web of Science ®Google Scholar
• Leon M. B., Baim D. S., Popma J. J., Gordon P. C., Cutlip D. E., Ho K. K., et al. A clinical trial comparing three antithrombotic‐drug regimens after coronary‐artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339: 1665–71
   PubMed Web of Science ®Google Scholar
• King S. B., III., Lembo N. J., Weintraub W. S., Kosinski A. S., Barnhart H. X., Kutner M. H., et al. A randomized trial comparing coronary angioplasty with coronary bypass surgery. Emory Angioplasty versus Surgery Trial (EAST). N Engl J Med 1994; 331: 1044–50
   PubMed Web of Science ®Google Scholar
• Hamm C. W., Reimers J., Ischinger T., Rupprecht H. J., Berger J., Bleifeld W. A randomized study of coronary angioplasty compared with bypass surgery in patients with symptomatic multivessel coronary disease. German Angioplasty Bypass Surgery Investigation (GABI). N Engl J Med 1994; 331: 1037–43
   PubMed Web of Science ®Google Scholar
• CABRI Trial Participants. First‐year results of CABRI (Coronary Angioplasty versus Bypass Revascularisation Investigation). Lancet 1995; 346: 1179–84
   PubMed Web of Science ®Google Scholar
• Henderson R. A., Pocock S. J., Sharp S. J., Nanchahal K., Sculpher M. J., Buxton M. J., et al. Long‐term results of RITA‐1 trial: clinical and cost comparisons of coronary angioplasty and coronary‐artery bypass grafting. Randomised Intervention Treatment of Angina. Lancet 1998; 352: 1419–25
   PubMed Web of Science ®Google Scholar
• BARI Investigators. Five‐year clinical and functional outcome comparing bypass surgery and angioplasty in patients with multivessel coronary disease. A multicenter randomized trial. Writing Group for the Bypass Angioplasty Revascularization Investigation (BARI) Investigators. JAMA 1997; 277: 715–21
   Google Scholar
• SoS Investigators. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial. Lancet 2002; 360: 965–70
   PubMed Web of Science ®Google Scholar
• Legrand V. M., Serruys P. W., Unger F., van Hout B. A., Vrolix M. C., Fransen G. M., et al. Three‐year outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease. Circulation 2004; 109: 1114–20
   PubMed Web of Science ®Google Scholar
• Kastrati A., Schomig A., Dirschinger J., Mehilli J., Dotzer F., von Welser N., et al. Randomized trial comparing stenting with balloon angioplasty in small vessels in patients with symptomatic coronary artery disease. ISAR‐SMART Study Investigators. Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries. Circulation 2000; 102: 2593–8
   PubMed Web of Science ®Google Scholar
• Salame M. Y., Verheye S., Mulkey S. P., Choronos N. A. F., King SB I. I. I., Crocker I. R., et al. The Effect of Endovascular Irradiation on Platelet Recruitment at Sites of Balloon Angioplasty in Pig Coronary Arteries. Circulation 2000; 101: 1087–90
   PubMed Web of Science ®Google Scholar
• Virmani R., Farb A., Kolodgie F. D. Histopathologic alterations after endovascular radiation and antiproliferative stents: similarities and differences. Herz 2002; 27: 1–6
   PubMed Web of Science ®Google Scholar
• Windecker S., Simon R., Klauss V., Eberli F. R., Roffi M., Pedrazzini G., et al. Randomized comparison of a titanium‐nitriode‐oxide‐coated stent with a stainless steel stent for coronary revascularization. The TiNOX Trial. Circulation 2005; 111: 2617–22
   PubMed Web of Science ®Google Scholar
• Hedman M., Hartikainen J., Syvänne M., Stjernvall J., Hedman A., Kivelä A., et al. Safety and feasibility of catheter‐based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in‐stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003; 107: 2677–83
   PubMed Web of Science ®Google Scholar
• Sousa J. E., Costa M. A., Abizaid A., Abizaid A. S., Feres F., Pinto I. M., et al. Lack of neointimal proliferation after implantation of sirolimus‐coated stents in human coronary arteries: a quantitative coronary angiography and three‐dimensional intravascular ultrasound study. Circulation 2001; 103: 192–5
   PubMed Web of Science ®Google Scholar
• Sousa J. E., Costa M. A., Sousa A. G., Abizaid A. C., Seixas A. C., Abizaid A. S., et al. Two‐year angiographic and intravascular ultrasound follow‐up after implantation of sirolimus‐eluting stents in human coronary arteries. Circulation 2003; 107: 381–3
   PubMed Web of Science ®Google Scholar
• Morice M. C., Serruys P. W., Sousa J. E., Fajadet J., Ban H. E., Perin M., et al. A randomized comparison of a sirolimus‐eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773–80
   PubMed Web of Science ®Google Scholar
• Sousa J. E., Morice M. C., P. W., et al. A randomised, double‐blind study with the Sirolimus‐eluting BxVelocity balloon expandable stent in the treatment of patients with de novo native coronary artery lesions. 2005, EuroPCR
   Google Scholar
• Holmes D. R., Jr., Leon M. B., Moses J. W., Popma J. J., Cutlip D., Fitzgerald P. J., et al. Analysis of 1‐year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus‐eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004; 109: 634–40
   PubMed Web of Science ®Google Scholar
• Grube E., Silber S., Hauptmann K. E., Mueller R., Buellesfeld L., Gerckens U., et al. TAXUS I: Six‐ and Twelve‐Month Results From a Randomized, Double‐Blind Trial on a Slow‐Release Paclitaxel‐Eluting Stent for De Novo Coronary Lesions. Circulation 2003; 107: 38–42
   PubMed Web of Science ®Google Scholar
• Stone G. W. Paclitaxel‐eluting stents: Update 2005. 2005, TCT
   Google Scholar
• Dawkins K. D., Grube E., Guagliumi G., Banning A. P., Zmudka K., Colombo A., et al. TAXUS VI Investigators. Clinical efficacy of polymer‐based paclitaxel‐eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug‐eluting stents in contemporary clinical practice. Circulation 2005; 112: 3306–13
   PubMed Web of Science ®Google Scholar
• Meredith I. T. Endeavor I. 2005, ESC
   Google Scholar
• Fajadet W., Wijns, Kuntz R. A Randomized trial to evaluate the safety and efficacy of the Medtronic AVE ABT‐578 eluting driver coronary stent in de novo native coronary artery lesion. 12 month follow‐up. 2005, ESC
   Google Scholar
• Morice M. ‐C. Jupiter II: Double blind randomised comparison of Janus eluting stent with the Technic Carbostent. 2005, ESC
   Google Scholar
• Costa R. A., Lansky A. J., Mintz G. S., Mehran R., Tsuchiya Y., Negoita M., et al. Angiographic results of the first human experience with everolimus‐eluting stents for the treatment of coronary lesions (the FUTURE I trial). Am J Cardiol 2005; 95: 113–6
   PubMed Web of Science ®Google Scholar
• Virmani R., Farb A., Guagliumi G., Kolodgie F. D. Drug‐eluting stents: caution and concerns for long‐term outcome. Coron Artery Dis 2004; 15: 313–20
   PubMed Web of Science ®Google Scholar
• Hausleiter J., Kastrati A., Wessely R., Dibra A., Mehilli J., Schratzenstaller T., , for the investigators of the individualizable durg‐eluting Stent System to Abrogate Restenosis Project, et al. Prevention of restenosis by a novel drug‐eluting stent system with a dose‐adjustable, polymer‐free, on‐site stent coating. Eur Heart J 2005; 26: 1475–81
   PubMed Web of Science ®Google Scholar
• Mehilli J., Kastrati A., Wessely R., Dibra A., Hausleiter J., Jaschke B., et al. Intracoronary Stenting and Angiographic Restenosis–Test Equivalence Between 2 Drug‐Eluting Stents (ISAR‐TEST) Trial Investigators. Randomized trial of a nonpolymer‐based rapamycin‐eluting stent versus a polymer‐based paclitaxel‐eluting stent for the reduction of late lumen loss. Circulation 2006; 113: 273–9
   PubMed Web of Science ®Google Scholar
• Gershlick A., De Scheerder I., Chevalier B., Stephens‐Lloyd A., Camenzind E., Vrints C., et al. Inhibition of restenosis with a paclitaxel‐eluting, polymer‐free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation 2004; 109: 487–93
   PubMed Web of Science ®Google Scholar
• Goy J. J., Stauffer J. C., Siegenthaler M., Benoit A., Seydoux C. A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXi trial. J Am Coll Cardiol 2005; 45: 308–11
   PubMed Web of Science ®Google Scholar
• Windecker S., Remondino A., Eberli F. R., Juni P., Raber L., Wenaweser P., et al. Sirolimus‐eluting and paclitaxel‐eluting stents for coronary revascularization. N Engl J Med 2005; 353: 653–62
   PubMed Web of Science ®Google Scholar
• Morice M. ‐C. A prospective, randomised, multicenter comparison of the Cypher® sirolimus‐eluting and the Taxus® paclitaxel‐eluting stent systems. 2005, ACC
   Google Scholar
• Dibra A., Kastrati A., Mehilli J., Pache J., Schuhlen H., von Beckerath N., , ISAR‐DIABETES Study Investigators, et al. Paclitaxel‐eluting or sirolimus‐eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005; 353: 663–70
   PubMed Web of Science ®Google Scholar
• Kastrati A., Mehilli J., von Beckerath N., Dibra A., Hausleiter J., Pache J., , ISAR‐DESIRE Study Investigators, et al. Sirolimus‐eluting stent or paclitaxel‐eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in‐stent restenosis: a randomized controlled trial. JAMA 2005; 293: 165–71
   PubMed Web of Science ®Google Scholar
• Moliterno D. J. Healing Achilles‐sirolimus versus paclitaxel. N Engl J Med 2005; 353: 724–7
   PubMed Web of Science ®Google Scholar
• Sabate M., Jimenez‐Quevedo, Angiolillo D., Gomez‐Hospital J. A., Alfonso F., Hernandez‐Antolin R., et al. Randomized comparison of sirolimus‐eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus‐eluting stent (DIABETES) trial. Circulation 2005; 112: 2175–83
   PubMed Web of Science ®Google Scholar
• Ardissino D., Cavallini C., Bramucci E., Indolfi C., Marzocchi A., Manari A., et al. Sirolimus‐Eluting vs Uncoated Stents for Prevention of Restenosis in Small Coronary Arteries: A Randomized Trial. JAMA 2004; 292: 2727–34
   PubMed Web of Science ®Google Scholar
• Stone G. W., Ellis S. G., Cannon L., Mann J. T., Greenberg J. D., Spriggs D., et al. Comparison of a polymer‐based paclitaxel‐eluting stent with a bare metal stent in patients with complex coronary artery disease. JAMA 2005; 294: 1215–23
   PubMed Web of Science ®Google Scholar
• Schofer J., Schluter M., Gershlick A. H., Wijns W., Garcia E., Schampaert E., et al. Sirolimus‐eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double‐blind, randomised controlled trial (E‐SIRIUS). Lancet 2003; 362: 1093–9
   PubMed Web of Science ®Google Scholar
• Schampaert E., Cohen E. A., Schluter M., Reeves F., Traboulsi M., Title L. M., et al. The Canadian study of the sirolimus‐eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C‐SIRIUS). J Am Coll Cardiol 2004; 43: 1110–5
   PubMed Web of Science ®Google Scholar
• Kastrati A., Dibra A., Eberle S., Mehilli J., Suárez de Lezo J., Goy J. ‐J., et al. Sirolimus‐Eluting Stents vs Paclitaxel‐Eluting Stents in Patients With Coronary Artery Disease. Meta‐analysis of Randomized Trials. JAMA 2005; 294: 819–25
   PubMed Web of Science ®Google Scholar
• Holmes D. R., Popma J., Kuntz R., Fitzgerald P. J., Teirstein P. S., Satler L., et al. The SISR Trial. A multicenter, randomized, study of the Sirolimus‐eluting Bx Velocity® stent vs intravascular brachytherapy in the treatment of patients with in‐stent restenotic coronary artery lesions. 2005, TCT
   Google Scholar
• Radke P. W., Kobella S., Kaiser A., Franke A., Schubert D., Grube E., et al. Treatment of in‐stent restenosis using a paclitaxel‐eluting stent: acute results and long‐term follow‐up of a matched‐pair comparison with intracoronary beta‐radiation therapy. Eur Heart J 2004; 25: 920–5
   PubMedGoogle Scholar
• Serruys P. W., Lemos P. A., van Hout B. A. Arterial Revascularisation Therapies Study part II Steering Committee and Investigators. Sirolimus eluting stent implantation for patients with multivessel disease: rationale for the Arterial Revascularisation Therapies Study part II (ARTS II). Heart 2004; 90: 995–8
   PubMed Web of Science ®Google Scholar
• Valgimigli M., van Mieghem C. A. G., Ong A. T. L., Aoki J., Rodriguez Granillo G. A., McFadden E. P., et al. Short‐ and long term clinical outcome after drug‐eluting stent implantation for the percutaneous treatment of left main coronary artery disease. Insights from the rapamycin‐eluting and Taxus stent evaluated at Rotterdam cardiology hospital registries (RESEARCH and T‐SEARCH). Circulation 2005; 111: 1383–89
   PubMed Web of Science ®Google Scholar
• Iakovou I., Schmidt T., Bonizzoni E., Ge L., Sangiorgi G. M., Stankovic G., et al. Incidence, Predictors, and Outcome of Thrombosis After Successful Implantation of Drug‐Eluting Stents. JAMA 2005; 2126–30, 293
   Google Scholar